NASDAQ:BFRI - Nasdaq - US09077D2099 - Common Stock - Currency: USD
BFRI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. BFRI may be in some trouble as it scores bad on both profitability and health. BFRI is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -80.35% | ||
ROE | -400.61% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 50.14% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.92 | ||
Debt/FCF | N/A | ||
Altman-Z | -7.64 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.72 | ||
Quick Ratio | 1.17 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
0.72
+0.03 (+4.33%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 0.17 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 1.44 | ||
P/tB | 1.45 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -80.35% | ||
ROE | -400.61% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 50.14% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.92 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 14.25% | ||
Cap/Sales | 0.16% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.72 | ||
Quick Ratio | 1.17 | ||
Altman-Z | -7.64 |